Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haffner, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haffner, S. M.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 21, Issue 1 160-178, Copyright © 1998 by American Diabetes Association

ARTICLES

Management of dyslipidemia in adults with diabetes

SM Haffner
Department of Medicine, University of Texas Health Science Center at San Antonio 78284-7873, USA.

Subjects with diabetes have a greatly increased risk of CHD, which is only partially related to their elevated glucose. Other factors such as insulin resistance and dyslipidemia are likely to be important. The type of dyslipidemia that is most characteristic of type 2 diabetic subjects is elevated triglycerides and decreased HDL cholesterol levels, although all lipoproteins have compositional abnormalities. Surprisingly few good prospective studies of lipoprotein levels in relation to CHD have been done in diabetic subjects. Available studies suggest that low HDL cholesterol may be the most important risk factor for CHD in observational studies. In studies in which total cholesterol and triglyceride were done, cholesterol and triglycerides were risk factors for CHD, although triglycerides were often a stronger predictor. However, the strength of triglyceride as a risk factor for CHD may depend partially on its association with other variables (e.g., hypertension, plasminogen activator inhibitor 1 [PAI-1], etc.). In clinical trials in diabetic subjects, LDL reduction with statins has led to significant reductions in CHD incidence. In addition, overall mortality was reduced with statin therapy, although the results were not statistically significant. Gemfibrozil has led to reductions in CHD incidence in diabetic subjects, although the results were not statistically significant perhaps because of low sample size. Regarding lipoproteins and CHD risk in diabetic patients, the very positive results of statin trials point to LDL cholesterol being more important than previous realized. Apparently, having a borderline high LDL cholesterol (between 130 and 160 mg/dl) in a diabetic patient is equivalent to a much higher LDL cholesterol in terms of CHD risk for a nondiabetic subject. Therefore, the primary target of therapy in diabetic patients is lowering LDL cholesterol (or possibly, non-HDL cholesterol). Statins are the preferred pharmacological agent in this situation. Once LDL cholesterol levels have been lowered, attention can be given to treatment of residual hypertriglyceridemia and low HDL. The goal here is weight reduction and increased exercise. However, for selected patients, combining a fibric acid (or low-dose nicotinic acid) with a statin also can be considered. Reduction of LDL levels should take priority over reduction of triglycerides in combined hyperlipidemia because of the proven safety of the statin class of drugs as well as greater reduction in CHD incidence.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Therapeutic Advances in Cardiovascular DiseaseHome page
J. R. Romero, J. Morris, and A. Pikula
Review: Stroke prevention: modifying risk factors
Therapeutic Advances in Cardiovascular Disease, August 1, 2008; 2(4): 287 - 303.
[Abstract] [PDF]

Home page
 The Diabetes EducatorHome page
S. Metghalchi, M. Rivera, L. Beeson, A. Firek, M. De Leon, Z. R. Cordero-MacIntyre, and H. Balcazar
Improved Clinical Outcomes Using a Culturally Sensitive Diabetes Education Program in a Hispanic Population
The Diabetes Educator, July 1, 2008; 34(4): 698 - 706.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
I. J. Goldberg, Y. Hu, H.-L. Noh, J. Wei, L. A. Huggins, M. G. Rackmill, H. Hamai, B. N. Reid, W. S. Blaner, and L.-S. Huang
Decreased Lipoprotein Clearance Is Responsible for Increased Cholesterol in LDL Receptor Knockout Mice With Streptozotocin-Induced Diabetes
Diabetes, June 1, 2008; 57(6): 1674 - 1682.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
American Diabetes Association
Standards of Medical Care in Diabetes--2008
Diabetes Care, January 1, 2008; 31(Supplement_1): S12 - S54.
[Full Text] [PDF]

Home page
 NEJMHome page
J. D. Brunzell
Hypertriglyceridemia
N. Engl. J. Med., September 6, 2007; 357(10): 1009 - 1017.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
American Diabetes Association
Standards of Medical Care in Diabetes--2007
Diabetes Care, January 1, 2007; 30(suppl_1): S4 - S41.
[Full Text] [PDF]

Home page
 EndocrinologyHome page
H. Zitzer, W. Wente, M. B. Brenner, S. Sewing, K. Buschard, J. Gromada, and A. M. Efanov
Sterol Regulatory Element-Binding Protein 1 Mediates Liver X Receptor-{beta}-Induced Increases in Insulin Secretion and Insulin Messenger Ribonucleic Acid Levels
Endocrinology, August 1, 2006; 147(8): 3898 - 3905.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. Shepherd, P. Barter, R. Carmena, P. Deedwania, J.-C. Fruchart, S. Haffner, J. Hsia, A. Breazna, J. LaRosa, S. Grundy, et al.
Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes: The Treating to New Targets (TNT) study.
Diabetes Care, June 1, 2006; 29(6): 1220 - 1226.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
American Diabetes Association
Standards of Medical Care in Diabetes-2006
Diabetes Care, January 1, 2006; 29(suppl_1): S4 - S42.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J. Liu, C. Sempos, R. P. Donahue, J. Dorn, M. Trevisan, and S. M. Grundy
Joint Distribution of Non-HDL and LDL Cholesterol and Coronary Heart Disease Risk Prediction Among Individuals With and Without Diabetes
Diabetes Care, August 1, 2005; 28(8): 1916 - 1921.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A. Festa, K. Williams, A. J.G. Hanley, J. D. Otvos, D. C. Goff, L. E. Wagenknecht, and S. M. Haffner
Nuclear Magnetic Resonance Lipoprotein Abnormalities in Prediabetic Subjects in the Insulin Resistance Atherosclerosis Study
Circulation, June 28, 2005; 111(25): 3465 - 3472.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
American Diabetes Association
Standards of Medical Care in Diabetes
Diabetes Care, January 1, 2005; 28(suppl_1): S4 - S36.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
N. F. Sheard, N. G. Clark, J. C. Brand-Miller, M. J. Franz, F. X. Pi-Sunyer, E. Mayer-Davis, K. Kulkarni, and P. Geil
Dietary Carbohydrate (Amount and Type) in the Prevention and Management of Diabetes: A statement by the American Diabetes Association
Diabetes Care, September 1, 2004; 27(9): 2266 - 2271.
[Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
D.J. Betteridge
Treating dyslipidaemia in the patient with type 2 diabetes
Eur. Heart J. Suppl., July 1, 2004; 6(suppl_C): C28 - C33.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
H. Fukushima, S. Sugiyama, O. Honda, S. Koide, S. Nakamura, T. Sakamoto, M. Yoshimura, H. Ogawa, D. Fujioka, and K. Kugiyama
Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type ii diabetes mellitus
J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2219 - 2224.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
A. M Coulston
Cardiovascular disease risk in women with diabetes needs attention
Am. J. Clinical Nutrition, June 1, 2004; 79(6): 931 - 932.
[Full Text] [PDF]

Home page
 J Am Board Fam MedHome page
G. Putzer, R. Roetzheim, A. M. Ramirez, K. Sneed, H. J. Brownlee Jr, and R. J. Campbell
Compliance with Recommendations for Lipid Management among Patients with Type 2 Diabetes in an Academic Family Practice
J Am Board Fam Med, March 1, 2004; 17(2): 101 - 107.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
D. Schering and S. Kasten
The Link Between Diabetes and Cardiovascular Disease
Journal of Pharmacy Practice, February 1, 2004; 17(1): 61 - 65.
[Abstract] [PDF]

Home page
 JAMAHome page
S. H. Saydah, J. Fradkin, and C. C. Cowie
Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed Diabetes
JAMA, January 21, 2004; 291(3): 335 - 342.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Screening for Type 2 Diabetes
Diabetes Care, January 1, 2004; 27(90001): s11 - 14.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
Standards of Medical Care in Diabetes
Diabetes Care, January 1, 2004; 27(90001): s15 - 35.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
Dyslipidemia Management in Adults With Diabetes
Diabetes Care, January 1, 2004; 27(90001): s68 - 71.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J. S. Stroup, M. P. Kane, and R. S. Busch
The Antilipidemic Effects of Ezetimibe in Patients With Diabetes
Diabetes Care, October 1, 2003; 26(10): 2958 - 2959.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
K. Winkler, T. Konrad, S. Fullert, I. Friedrich, R. Destani, M. W. Baumstark, K. Krebs, H. Wieland, and W. Marz
Pioglitazone Reduces Atherogenic Dense LDL Particles in Nondiabetic Patients With Arterial Hypertension: A double-blind, placebo-controlled study
Diabetes Care, September 1, 2003; 26(9): 2588 - 2594.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
W. Lu, H. E. Resnick, K. A. Jablonski, K. L. Jones, A. K. Jain, Wm. J. Howard, D. C. Robbins, and B. V. Howard
Non-HDL Cholesterol as a Predictor of Cardiovascular Disease in Type 2 Diabetes: The Strong Heart Study
Diabetes Care, January 1, 2003; 26(1): 16 - 23.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Screening for Type 2 Diabetes
Diabetes Care, January 1, 2003; 26(90001): s21 - 24.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
Standards of Medical Care for Patients With Diabetes Mellitus
Diabetes Care, January 1, 2003; 26(2007): S33 - S50.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
Management of Dyslipidemia in Adults With Diabetes
Diabetes Care, January 1, 2003; 26(90001): s83 - 86.
[Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
O. I Bermudez, W. Velez-Carrasco, E. J Schaefer, and K. L Tucker
Dietary and plasma lipid, lipoprotein, and apolipoprotein profiles among elderly Hispanics and non-Hispanics and their association with diabetes
Am. J. Clinical Nutrition, December 1, 2002; 76(6): 1214 - 1221.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. Winkler, C. Abletshauser, M. M. Hoffmann, I. Friedrich, M. W. Baumstark, H. Wieland, and W. Marz
Effect of Fluvastatin Slow-Release on Low Density Lipoprotein (LDL) Subfractions in Patients with Type 2 Diabetes Mellitus: Baseline LDL Profile Determines Specific Mode of Action
J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5485 - 5490.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
T. Jensen, Q. Truong, M. Frandsen, B. Dinesen, and S. Stender
Comparison of a Homogeneous Assay With a Precipitation Method for the Measurement of HDL Cholesterol in Diabetic Patients
Diabetes Care, November 1, 2002; 25(11): 1914 - 1918.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. M. Nathan
Initial Management of Glycemia in Type 2 Diabetes Mellitus
N. Engl. J. Med., October 24, 2002; 347(17): 1342 - 1349.
[Full Text] [PDF]

Home page
 Diabetes Spectr.Home page
B. A. Kroner
Common Drug Pathways and Interactions
Diabetes Spectr, October 1, 2002; 15(4): 249 - 255.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
T. C. Keyserling, C. D. Samuel-Hodge, A. S. Ammerman, B. E. Ainsworth, C. F. Henriquez-Roldan, T. A. Elasy, A. H. Skelly, L. F. Johnston, and S. I. Bangdiwala
A Randomized Trial of an Intervention to Improve Self-Care Behaviors of African-American Women With Type 2 Diabetes: Impact on physical activity
Diabetes Care, September 1, 2002; 25(9): 1576 - 1583.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
R G. Barr, D. M. Nathan, J. B. Meigs, and D. E. Singer
Tests of Glycemia for the Diagnosis of Type 2 Diabetes Mellitus
Ann Intern Med, August 20, 2002; 137(4): 263 - 272.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
S. M. Haffner and R. B. Goldberg
New Strategies for the Treatment of Diabetic Dyslipidemia
Diabetes Care, July 1, 2002; 25(7): 1237 - 1239.
[Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
K. Winkler, I. Friedrich, M. W Baumstark, H. Wieland, and W. Marz
Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with type 2 diabetes mellitus
The British Journal of Diabetes & Vascular Disease, March 1, 2002; 2(2): 143 - 148.
[Abstract] [PDF]

Home page
 Journal of the American Dental AssociationHome page
M. GLICK
Screening for traditional risk factors for cardiovascular disease: A review for oral health care providers
J Am Dent Assoc, March 1, 2002; 133(3): 291 - 300.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
D. B. Sacks, D. E. Bruns, D. E. Goldstein, N. K. Maclaren, J. M. McDonald, and M. Parrott
Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus
Clin. Chem., March 1, 2002; 48(3): 436 - 472.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. J. Franz, J. P. Bantle, C. A. Beebe, J. D. Brunzell, J.-L. Chiasson, A. Garg, L. A. Holzmeister, B. Hoogwerf, E. Mayer-Davis, A. D. Mooradian, et al.
Evidence-Based Nutrition Principles and Recommendations for the Treatment and Prevention of Diabetes and Related Complications
Diabetes Care, January 1, 2002; 25(1): 148 - 198.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
Standards of Medical Care for Patients With Diabetes Mellitus
Diabetes Care, January 1, 2002; 25(1): 213 - 229.
[Full Text] [PDF]

Home page
 ChestHome page
J. B. Braunstein, A. Cheng, G. Cohn, M. Aggarwal, C. M. Nass, and R. S. Blumenthal
Lipid Disorders : Justification of Methods and Goals of Treatment
Chest, September 1, 2001; 120(3): 979 - 988.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
The Diabetes Atorvastatin Lipid Intervention DALI
The Effect of Aggressive Versus Standard Lipid Lowering by Atorvastatin on Diabetic Dyslipidemia: The DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia
Diabetes Care, August 1, 2001; 24(8): 1335 - 1341.
[Abstract] [Full Text] [PDF]

Home page
 Clin. DiabetesHome page
R. R. Henry
Preventing Cardiovascular Complications of Type 2 Diabetes: Focus on Lipid Management
Clin. Diabetes, July 1, 2001; 19(3): 113 - 120.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
F. Ledru, P. Ducimetiere, S. Battaglia, D. Courbon, F. Beverelli, L. Guize, J.-L.e. Guermonprez, and B. Diebold
New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study
J. Am. Coll. Cardiol., May 1, 2001; 37(6): 1543 - 1550.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
C. M. Clark Jr., J. E. Fradkin, R. G. Hiss, R. A. Lorenz, F. Vinicor, and E. Warren-Boulton
The National Diabetes Education Program, Changing the Way Diabetes Is Treated: Comprehensive diabetes care
Diabetes Care, April 1, 2001; 24(4): 617 - 618.
[Full Text]

Home page
 Diabetes CareHome page
P. Spallarossa, M. Schiavo, P. Rossettin, S. Cordone, L. Olivotti, R. Cordera, and C. Brunelli
Sulfonylurea Treatment of Type 2 Diabetic Patients Does Not Reduce the Vasodilator Response to Ischemia
Diabetes Care, April 1, 2001; 24(4): 738 - 742.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
I. J. Goldberg
Diabetic Dyslipidemia: Causes and Consequences
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 965 - 971.
[Full Text]

Home page
 Diabetes CareHome page
M. I. Harris
Racial and Ethnic Differences in Health Care Access and Health Outcomes for Adults With Type 2 Diabetes
Diabetes Care, March 1, 2001; 24(3): 454 - 459.
[Abstract] [Full Text]

Home page
 Diabetes CareHome page
S. D.J.M. Kanters, J.-D. Banga, A. Algra, R. C.J.M. Frijns, J. J. Beutler, and R. Fijnheer
Plasma Levels of Cellular Fibronectin in Diabetes
Diabetes Care, February 1, 2001; 24(2): 323 - 327.
[Abstract] [Full Text]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
M. Kirby
Commentary: Audit of mortality in type 2 diabetes
The British Journal of Diabetes & Vascular Disease, January 1, 2001; 1(1): 55 - 56.
[PDF]

Home page
 HeartHome page
J. ARMITAGE and R. COLLINS
Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials
Heart, October 1, 2000; 84(4): 357 - 360.
[Full Text]

Home page
 JAMAHome page
M. B. Elam, D. B. Hunninghake, K. B. Davis, R. Garg, C. Johnson, D. Egan, J. B. Kostis, D. S. Sheps, E. A. Brinton, and for the ADMIT Investigators
Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients With Diabetes and Peripheral Arterial Disease: The ADMIT Study: A Randomized Trial
JAMA, September 13, 2000; 284(10): 1263 - 1270.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
C. M. Clark, J. E. Fradkin, R. G. Hiss, R. A. Lorenz, F. Vinicor, and E. Warren-Boulton
Promoting Early Diagnosis and Treatment of Type 2 Diabetes: The National Diabetes Education Program
JAMA, July 19, 2000; 284(3): 363 - 365.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Oberman
Hypertriglyceridemia and Coronary Heart Disease
J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2098 - 2105.
[Full Text]

Home page
 CirculationHome page
S. M. Haffner, L. Mykkanen, A. Festa, J. P. Burke, and M. P. Stern
Insulin-Resistant Prediabetic Subjects Have More Atherogenic Risk Factors Than Insulin-Sensitive Prediabetic Subjects : Implications for Preventing Coronary Heart Disease During the Prediabetic State
Circulation, March 7, 2000; 101(9): 975 - 980.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
S. M. Haffner, C. M. Alexander, T. J. Cook, S. J. Boccuzzi, T. A. Musliner, T. R. Pedersen, J. Kjekshus, K. Pyorala, and for the Scandinavian Simvastatin Survival Study Gr
Reduced Coronary Events in Simvastatin-Treated Patients With Coronary Heart Disease and Diabetes or Impaired Fasting Glucose Levels: Subgroup Analyses in the Scandinavian Simvastatin Survival Study
Arch Intern Med, December 13, 1999; 159(22): 2661 - 2667.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. M. Grundy, I. J. Benjamin, G. L. Burke, A. Chait, R. H. Eckel, B. V. Howard, W. Mitch, S. C. Smith Jr, and J. R. Sowers
Diabetes and Cardiovascular Disease : A Statement for Healthcare Professionals From the American Heart Association
Circulation, September 7, 1999; 100(10): 1134 - 1146.
[Full Text] [PDF]

Home page
 JAMAHome page
F. Vinicor
When Is Diabetes Diabetes?
JAMA, April 7, 1999; 281(13): 1222 - 1224.
[Full Text] [PDF]

Home page
 NEJMHome page
D. A. Redelmeier, S. H. Tan, and G. L. Booth
The Treatment of Unrelated Disorders in Patients with Chronic Medical Diseases
N. Engl. J. Med., May 21, 1998; 338(21): 1516 - 1520.
[Abstract] [Full Text] [PDF]